{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-116496","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.092655+00:00","generated_at":"2026-06-22T01:45:21.461027+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aprea Therapeutics Q3 net loss narrows to $4.0M; cash $33.1M; ATRN-119 Phase 1 initiated","bullets":["Net loss of $4.0M ($0.12 per share) vs $9.5M ($0.45) in Q3 2021; cash and equivalents $33.1M (down from $53.1M at Dec 2021).","R&D expenses fell to $1.1M from $6.0M due to trial close-outs and Atrin acquisition cost reductions.","Phase 1 trial of ATR inhibitor ATRN-119 opened for enrollment; expects 1-2 additional sites in Q4 2022.","WEE1 inhibitor ATRN-W1051 in preclinical stage; IND-enabling studies anticipated in Q4 2022.","APR-548 Phase 1 trial closed; no ongoing clinical trials of eprenetapopt (APR-246)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-116496","json":"https://secwatch.observer/filing/0001104659-22-116496.json","markdown":"https://secwatch.observer/filing/0001104659-22-116496.md","text":"https://secwatch.observer/filing/0001104659-22-116496.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922116496/0001104659-22-116496-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922116496/tm2230091d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:45:21.461027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b6f646c6cbd03c733197e42ae8c819f1242b583c","claim":"Aprea Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss was $4.0 million, or $0.12 per share, EPS $0.12 per share.","evidence_excerpt":"Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and nine months ended September 30, 2022 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922116496/0001104659-22-116496-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss was $4.0 million, or $0.12 per share"},{"label":"EPS","value":"$0.12 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}